The aim of this study was to identify genes involved in human placentation. To do this, differential gene expression was assessed in the decidua (placental bed) from pre-eclamptic and normotensive pregnancies using the polymerase chain reaction (PCR)-based subtractive technique of representational difference analysis. A novel aspartyl protease (cathepsin D-like) cDNA sequence was isolated by virtue of its over-expression in the pre-eclamptic decidual sample tested. It was designated DAP-1 (for Decidual Aspartyl Protease 1). Using DAP-1 primer sequences a second cDNA (DAP-2) was subsequently isolated from decidual RNA by reverse transcription (RT)-PCR and found to be identical to DAP-1 apart from 80 additional and consecutive base pairs in the N-terminal coding region. In DAP-2, a stop codon within the unique 80 bp sequence was predicted to terminate translation immediately before the consensus active site residues. While Southern blotting was used to show that there are two loci with homology to DAP-1 in the human genome, it is postulated that alternative pre-mRNA splicing of the 80 bp exon is involved in the regulated expression of active (DAP-1) and inactive (DAP-2) forms of this novel protease; a mechanism similar to that involved in the regulated expression of Caspase-2, a protease involved in apoptosis. In other systems the regulation of alternative splicing is indicated by tissue specificity and developmental stage specificity of the various spliced products. In this context it was demonstrated that whereas DAP-1 was the major transcript expressed in decidua, the pattern was reversed in the adjacent placental tissue. It is proposed that tissue and developmental stage-specific expression of the DAP protease are important for the normal development and function of the uteroplacental tissues and that dysregulation of the control of DAP gene splicing may play a role in abnormal placentation, like that seen in pre-eclampsia.
Introduction
Human placentation involves a complex interaction between fetal and maternal tissues. While several proteins that play a role in early placentation have been identified, a complete understanding of the cellular and molecular components involved is just beginning (Cross et al., 1994; Kliman, 1994) . A central feature of human placentation involves the formation of columns of cytotrophoblasts that invade the maternal uterine tissues and in particular the maternal decidual vasculature. This invasion extends along the spiral arteries, through the full thickness of the decidua, to the inner third of the myometrium. The cytotrophoblasts replace the endothelial cell lining of the maternal spiral arteries and destroy the underlying extracellular matrix and vascular smooth muscle. These spiral arteries are thus transformed into large diameter vessels of low resistance which maximizes maternal blood flow into the intervillous space (Cross et al., 1994; Kliman 1994; Zhou et al., 1997a) .
Abnormal placentation with shallow trophoblastic spiral artery invasion and inadequate maternal spiral artery transformation is a characteristic feature of pre-eclampsia, the most common serious medical disorder of human pregnancy (Robertson et al., 1986; Zhou et al., 1997b) . It is postulated that, in pre-eclampsia, failure of spiral artery transformation subsequently leads to placental hypoxia and this in turn leads to the release by the placenta of a factor(s) which mediates widespread maternal endothelial cell dysfunction (Higgins and Brennecke, 1998) . In an attempt to elucidate molecular events associated with abnormal placentation we used a new molecular technique, called representational difference analysis (cDNA-RDA; Hubank and Schatz, 1994) , to examine differential gene expression in normal and pre-eclamptic decidual (placental bed) tissues. In this paper we report the characterization of novel aspartyl protease gene sequences that were identified using this approach.
Materials and methods

Reagents
Acrylamide, herring sperm DNA and morpholinopropane-sulphinic acid (MOPS) were purchased from Roche Diagnostics, Australia. Agarose, bisacrylamide, deoxynucleotide triphosphates and pGEM DNA markers were obtained from Promega Corporation, Castle Hill, NSW, Australia. Guanidine thiocyanate was purchased from Fluka (Buchs, Switzerland). Phenol (Wako special grade) was obtained from Novachem (Melbourne, Australia). The oligonucleotides described in the original protocol by Hubank and Schatz (1994) were synthesized at Monash University, Melbourne, Australia. Mung Bean Nuclease and T 4 DNA ligase were bought from Promega, Australia. DpnII was obtained from New England Biolabs. All polymerase chain reactions (PCR) reactions were performed using 5 U of Taq DNA polymerase (Gibco BRL) in 1ϫPCR buffer (Gibco BRL; 10 mmol/l Tris-HCl pH 8.3, 50 mmol/l KCl, 4 mmol/l MgCl 2 ). Glycogen and yeast RNA was purchased from Boehringer Mannheim. DNA extraction from agarose gels was carried out using a Quiex gel extraction kit (Qiagen), according to the manufacturer's instructions.
Sample collection
Placental bed biopsies (decidua) were obtained (with Institutional Research and Ethics Committee approvals) during Caesarean section from eleven normal patients and one patient with preeclampsia. The tissues were immediately frozen in liquid nitrogen and stored at -80°C until processed. The patient with pre-eclampsia was diagnosed according to internationally agreed criteria (Davey and MacGillivray, 1988) . Eight placentae were collected from women who delivered singleton infants by elective Caesarean section at term. Within 10 min of delivery, placental tissue was collected and RNA was immediately extracted.
RNA isolation and preparation of cDNA
Total cytoplasmic RNA was isolated by a guanidinium thiocyanate/ phenol chloroform method (Chomczynski and Sacchi, 1987) . The quantity of RNA recovered was established spectrophotometrically and its integrity assessed by electrophoresis on a 1% non-denaturing agarose gel (Sambrook et al., 1989) . PolyA ϩ mRNA was isolated from total RNA using a commercial system (PolyATtract mRNA isolation kit, Promega). Double-stranded cDNA was prepared by reverse transcription (RT) of the polyA ϩ mRNA using the RiboClone cDNA Synthesis Systems AMV RT kit (Promega), according to the manufacturer's instructions.
RDA of cDNA
RDA of cDNA involves the digestion of similar cDNA populations with the restriction enzyme DpnII followed by adaptor ligation and PCR-mediated amplification of the restriction fragments. If an amplifiable restriction fragment (the target gene) exists in one representation of cDNA (the Tester) and is either absent or in lower abundance in another (the Driver), a kinetic enrichment of the target is achieved by subtractive hybridization of the Tester in the presence of excess Driver. Successive iterations of the subtractive hybridization/ PCR amplification produce ethidium visible bands on an agarose gel corresponding to the enriched target. Difference products can be excised from the gel, and cloned into a plasmid vector for detailed molecular characterization. To selectively amplify genes that are upregulated in pre-eclampsia, a pool of cDNA prepared from three normal placental bed tissues was used as the Driver; the Tester was cDNA prepared from placental bed tissue from a patient with preeclampsia. RDA of cDNA was implemented according to the method of Hubank and Schatz (1994) , using the Tester and Driver cDNA described above. Briefly, three rounds of hybridization/amplification were carried out, generating difference products 1, 2 and 3 (DP1, DP2 and DP3). The ratios of Driver to Tester for DP1, 2 and 3 were 100:1, 800:1 and 400 000:1 respectively. All procedures were performed using plugged filter tips (ART; Continental Laboratory Products, San Diego, USA) and the PCR-mediated amplification was carried out in an OMNE thermocycler (Hybaid) using 0.5 ml tubes.
Cloning and sequencing cDNA fragments from DP3 were cloned blunt-ended into the Srf I site of the pCR-Script TM SK(ϩ) phagemid [pCR-Script™SK(ϩ)
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Cloning Kit, Stratagene, La Jolla, CA, USA], according to the manufacturer's instructions. Double-stranded plasmid DNA were prepared from transformed E.coli cultures by the alkaline-sodium dodecyl sulphate (SDS) lysis procedure (Sambrook et al., 1989) . Sequencing reactions were performed on recombinant plasmids using a Dye Terminator kit (Perkin-Elmer, Norwalk, CT, USA). Sequencing analysis was performed using an Applied Biosystems ABI 377 automated sequencer (Perkin-Elmer, Norwalk, CT, USA). Sequence comparisons were made with sequences in GenBank using the computer program BLAST, residing at the Australian National Genomic Information Service (http://www.angis.org.au).
Northern blot analysis
Total RNA (20 µg) was denatured in formamide (35% v/v) and formaldehyde (12% v/v) for 10 min, size-fractionated on a 1% denaturing agarose gel and then capillary-blotted onto Hybond N membrane (Amersham, Castle Hill, NSW, Australia), as described previously (Freed et al., 1995) . An RNA ladder spanning 0.24-9.5 kb (Gibco BRL, Gaithersburg, MD, USA) was run on the gel to estimate transcript size. The cloned 253 bp cDNA fragment (25 ng) derived from DP3 (DAP-1) was radiolabelled with [α-32 P]dCTP (Amersham: 3000 Ci/mmol) using a random primer oligolabelling kit (Prime-a Gene ® Labelling Kit; Promega Corporation). Membranes were prehybridized at 42°C for 3 h in hybridization buffer containing 50% formamide, 5ϫSSPE (0.7 mol/l NaCl, 0.04 mol/l NaH 2 PO 4 ·H 2 O, 0.005 mol/l EDTA pH 7.4), 5ϫDenhardt's solution [1ϫDenhardt's contains 0.02% (w/v) each of BSA, Ficoll 400 and polyvinylpyrrolidone], 0.5% SDS and 0.5 mg/ml denatured herring sperm DNA. Hybridization of the radiolabelled probe to the membrane was carried out for 16 h at 42°C in hybridization buffer. The membrane was washed initially with 2ϫSSC (SSC consists of 0.15 mol/l NaCl, 0.017 mol/l sodium citrate pH 7.0)/ 0.1% SDS at room temperature (15 min), followed by a wash in 0.1ϫSSC/0.1% SDS at 50°C. Autoradiographs were obtained by exposure of the membrane to Kodak X-Omat AR film at -80°C.
Multiple tissue Northern blot
A commercial human multiple tissue Northern blot (Clontech) was probed with the 250 bp radiolabelled DAP-1 cDNA (described above) using the buffers and hybridization conditions provided by the manufacturer.
Southern blotting
Zooblot Human, sheep, rabbit, rat, mouse, chicken, lizard and frog DNA was a generous gift from Dr J.Hendry (Monash Medical Centre, Victoria, Australia). DNA (10 µg) was digested with EcoRI for 6 h at 37°C. In addition, human DNA (10 µg) was digested separately with HindIII, PstI and BamHI, for 6 h at 37°C. The DNA fragments were then loaded onto a 1% agarose gel and electrophoresed overnight in 1ϫTAE buffer. The size-fractionated DNA was Southern-blotted to Hybond N membrane (Amersham). The membrane was baked for 2 h at 80°C then prehybridized at 42°C in hybridization buffer. DAP-1 cDNA was radiolabelled as for the Northern blot analysis. Hybridization was performed overnight at 42°C in the same solution as for prehybridization with the exception that the 5ϫDenhardt's solution was omitted. The membrane was washed initially in 2ϫSSC/ 0.1% SDS at room temperature, then increasing stringency up to 0.5ϫSSC/0.1% SDS at 65°C.
RT-PCR
Primer design
The synthetic oligonucleotide primers that were used for semiquantitative RT-PCR analysis of DAP-1 were: forward, 5Ј-GC-AGGGCACACTGAAGAAGT-3Ј; and reverse, 5Ј-GGATGGAGAG-AACCAGCAGA-3Ј. These primers anneal to the corresponding (100% identical) region of DAP-2.
Reverse transcription
Total RNA samples used in RT-PCR experiments were treated with Proteinase K (100 ng/µl; Boehringer Mannheim) and then with RQ1 RNase-free DNase (0.2 U/µl; Promega) to remove contaminating chromosomal DNA. RNA (400 ng) was reverse-transcribed in a 20 µl reaction containing 200 U MMLV RT (Gibco BRL), 10 µmol/l oligo (dT) 15 primer (Promega Corporation), 500 µmol/l each of dATP, dCTP, dGTP and dTTP, 10 U RNAase inhibitor (Promega), 10 mmol/l DTT and 1ϫreverse transcriptase buffer (Gibco BRL; 50 mmol/l Tris-HCl pH 8.3, 75 mmol/l KCl, 3 mmol/l MgCl 2 ), at 35°C for 1 h. The reaction was terminated by incubation at 95°C for 5 min. PCR PCR-mediated amplification was carried out in a 20 µl reaction containing 1 µl from each RT reaction, 1 µmol/l each of the forward and reverse primers, 200 µmol/l each of dATP, dCTP, dGTP and dTTP, 2.5 U Taq DNA polymerase (Gibco BRL), 1ϫPCR buffer (Gibco BRL; 10 mmol/l Tris-HCl pH 8.3, 50 mmol/l KCl) and either 1.5 (for decidual samples) or 1.8 mmol/l MgCl 2 (placental samples). The reactions were overlaid with mineral oil (50 µl) and for decidual samples PCR was performed for 25 cycles (95°C, 1 min; 60°C, 1 min; 72°C, 1 min) using an ITC 100 Immersion Thermocycler (Bartelt Instruments, Australia). Placental samples were amplified using the same thermocycling profile for 35 cycles.
Southern blotting
Samples of each RT-PCR reaction (20% v/v ) were size-fractionated by electrophoresis on a 1.5% agarose gel in TAE buffer (0.04 mol/l Tris acetate, 0.001 mol/l EDTA, pH 8.4) followed by capillary blotting to Hybond N nylon membrane (Amersham) (Sambrook et al., 1989) . DNA size markers (pGEM DNA markers, Promega Corporation) were run in parallel to estimate fragment size. Membranes were prehybridized at 42°C for 3 h in the hybridization buffer described previously. 32 P-radiolabelled DAP-1 cDNA (as used for Northern analysis) was used as a probe to detect both DAP-1 and DAP-2 RT-PCR products.
Results
Cloning of novel aspartyl protease cDNA
For our RDA study we isolated RNA from decidual biopsies taken from normal and pre-eclamptic placental beds. The RNA from three normal tissues were pooled and used to prepare a Driver cDNA representation. The Tester cDNA representation was derived from a single pre-eclamptic tissue. Difference products (DP1, DP2 and DP3) were obtained at the end of each of the three iterative cycles (Figure 1) .
To facilitate molecular characterization, the major 347 bp cDNA amplicon in DP3 was purified from agarose gel and cloned into the plasmid vector pCRScript. The nucleotide sequence of the cloned cDNA fragment was determined and found to have no similarity with any sequences in the databases. In Northern blot analysis, using this cloned cDNA as a radiolabelled probe, no transcripts could be detected in any of the four tissue RNA used for RDA of cDNA (results not shown). Driver (D) and Tester (T) cDNA representations were prepared from normal (n ϭ 3) and pre-eclamptic (n ϭ 1) decidual RNA samples respectively. Difference products (DP1, DP2 and DP3) were obtained after each of the three iterative cycles. Samples from each step were subjected to agarose gel electrophoresis.
A second 253 bp cDNA amplicon was cloned from DP3 and found to predict a polypeptide sequence with 95% similarity to the N-terminal region of an aspartyl protease recently cloned from mouse kidney (kap, Mori et al., 1997) and 76% similarity with the corresponding region of human cathepsin D (Faust et al., 1985) . This N-terminal region contains the consensus catalytic site residues DTGSSNLW of aspartyl proteases (Figure 2) . Accordingly, the 253 bp cDNA amplicon was designated DAP-1 (for Decidual Aspartyl Protease 1).
In RT-PCR reactions (using internal DAP-1 primers) subsequently performed on decidual RNA (including those used for RDA), we found that a 289 bp cDNA amplicon (additional to the expected 209 bp DAP-1 fragment) was just visible in some reactions (shown later in Figure 5 ). Cloning and sequence analysis of this larger cDNA amplicon (DAP-2) revealed that it was identical to the DAP-1 cDNA amplicon, apart from an additional 80 bp sequence in the 5Ј end. This 80 bp sequence contains a stop codon that is in-frame with the putative protease coding sequence whereby the predicted polypeptide is truncated just short of the conserved catalytic site residues (Figure 3) .
To verify the putative up-regulation of DAP-1, Northern blot analysis was performed on the decidual RNA samples used for RDA of cDNA. A 1.5 kb transcript was found to be abundantly expressed in the Tester RNA sample but only weakly expressed in one of the three Driver RNA (Figure 4) . This transcript is similar in size to the mouse kap mRNA (1.6 kb; Mori et al., 1997) whereas the human cathepsin D mRNA is~2.2 kb (Faust et al., 1985) . It was considered appropriate to use DAP-1 as a probe since DAP-2 was only just detectable (in some decidual samples, including those used for RDA) by the far more sensitive RT-PCR methodology (shown later in Figure 5 ).
Differential expression of DAP-1 and DAP-2 in human uteroplacental tissues
Using primer sequences common to both DAP-1 and DAP-2 the relative expression of these transcripts in normal placental 
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(n ϭ 8) and decidual (n ϭ 12) tissues was determined by semi-quantitative RT-PCR. In decidua, DAP-1 is the predominant transcript whereas in the placenta the pattern is reversed ( Figure 5 ).
Expression of DAP in other human tissues
Hybridization of the radiolabelled DAP-1 cDNA probe to a commercial human multiple tissue Northern blot (Clontech) revealed that a 1.5 kb transcript was expressed most abundantly in the lung and moderately in the kidney. With the possibility of very weak expression in the heart no expression was detected in the other tissues examined (pancreas, smooth muscle, liver, placenta, and brain; Figure 6 ). This restricted expression profile for DAP is similar to that reported for kap in the mouse (Mori et al., 1997) and is in contrast with the ubiquitous distribution of cathepsin D mRNA expression (Faust et al., 1985; Tang and Wong, 1987) .
DAP sequences are conserved across species
Southern blot analysis revealed that DAP sequences are highly conserved in nature. Hybridization was detected in the genomes of the sheep, rabbit, rat, mouse, chicken lizard and frog ( Figure  7A ). Southern blots of human genomic DNA that had been digested independently with several different restriction endonucleases radiolabelled with a DAP-1 probe ( Figure 7B ). Since the probe contained no restriction sites for these endonucleases, the detection of two bands supports the notion that the cloned DAP-1 and DAP-2 cDNA are coded for by separate genes. . Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis of DAP-1 and DAP-2 mRNA expression in normal placentae (n ϭ 8) and decidua (n ϭ 12). RT-PCR was performed using the internal DAP-1 primers also common to DAP-2. Following agarose gel electrophoresis and Southern blotting, the membrane was hybridized with radiolabelled DAP-1 cDNA. The two normal (N1, N2) and one pre-eclamptic (PE) samples used in the cDNA representational difference analysis are indicated. 
Discussion
The complex molecular processes that contribute to the physiology and pathology of human placentation are poorly understood. Differential gene expression is likely to play a key role but, until recently, the techniques available to study differential gene expression have required relatively large quantities of RNA and have been of questionable utility for the isolation of minor differences. RDA offers a new approach to the assessment of differential gene expression (Lisitsyn et al., 1993) . Originally developed for the identification of differences between complex genomic DNA populations, it has since been adapted for the analysis of differential gene expression (cDNA-RDA; Hubank and Schatz, 1994) . This procedure is sensitive, results in the isolation of very few false-positive clones and opens the possibility of finding novel expressed genes.
The majority of studies utilizing cDNA-RDA have investigated differential gene expression in cell lines (Niwa et al., 1997; Arvand et al., 1998; Chang et al., 1998; Chu and Paul, 1998; . However, relatively fewer studies have adopted this technique to study differential gene expression in tissues (Lerner et al., 1996; Gruidl et al., 1997; Wada et al., 1997; Welford et al., 987 1998) . We have now successfully applied cDNA-RDA to isolate a novel aspartyl protease gene sequence DAP-1, by virtue of the over-expression of this gene in the decidua from a severe case of pre-eclampsia. This is the first reported use of RDA in obstetric research and the first molecular cloning of an aspartyl protease cDNA from uteroplacental tissues. We suggest that this technique could be used in a variety of reproductive studies to identify candidate genes.
The aspartyl proteases are a family of proteolytic enzymes that share a unique catalytic apparatus and mechanism, having apparently evolved from the same ancestral gene (Tang, 1979; Tang and Wong, 1987) . These enzymes usually function in acidic environments, a characteristic that limits their function to some specific locations in different organisms. Thus, the best known sources of mammalian aspartic proteases are stomach (for pepsin, gastricsin and chymosin), kidney (for renin), lysosomes (for cathepsin D) and endoplasmic reticulum (for cathepsin E). The function of these enzymes includes the digestion of proteins such as casein and clot milk (for gastric aspartic proteases), the biosynthesis of angiotensin I from angiotensinogen (for renin), and the degradation of intracellular and endocytosed proteins (for cathepsin D). The physiological function of cathepsin E is currently unknown.
The physiological function(s) of the putative DAP-1 protease is not known and is the subject of our continued investigation. Cathepsin D, the most similar (of the human aspartyl proteases) has multiple functions in different cellular compartments, including endosomal proteolysis of endocytosed proteins (Tang, 1979; Tang and Wong, 1987) , proteolytic activation (also endosomal) of secreted proteins such as growth factors and hormones (Diment et al., 1989) and cytokine-induced apoptosis (Deiss et al., 1996) . In addition a secreted form of cathepsin D has been implicated in controlling the migration of metastatic cells (Mignatti and Rifkin, 1993) and could also be involved in the control of cell migration during normal development (Deiss et al., 1996) . The restricted distribution of DAP mRNA expression to primarily lung and kidney (as shown by Northern blot analysis) is not in keeping with the ubiquitous distribution of cathepsin D mRNA expression (Tang and Wong 1987) . Rather, the distribution of DAP mRNA expression is in good agreement with the restricted distribution (primarily kidney and lung) of the recently cloned (and most similar) mouse kap mRNA, whose function is unknown (Mori et al., 1997) . Cathepsin D is expressed in the (non-pregnant) endometrium where its levels are increased in response to progesterone (Maudelonde et al., 1990; Bergqvist et al., 1996; Camier et al., 1996) but, as far as we are aware, there are no reports of a role for this protease in placentation.
With respect to the involvement of aspartyl proteases during pregnancy, renin is the only enzyme to have been the subject of detailed investigation in human gestational tissues. The potential for a locally acting renin-angiotensin system (RAS) to moderate regional haemodynamics and other organ functions by virtue of autocrine and/or paracrine actions has led to speculation that the impaired uteroplacental blood flow in preeclampsia may be related to alterations of the placental (locally acting) RAS. In this context it was found that there was a tendency toward increased expression of the renin gene in the placental extracts from pre-eclamptic pregnancies (Sowers et al., 1993) . However, although the existence of a complete RAS in the pregnant human uterus is generally accepted, some investigators have recently suggested that this long-held belief needs to be clarified, due to the apparent lack of (or unknown) specificity of the antibody and nucleic acid probes used to detect renin in uteroplacental tissues. In particular, the crossreactivity of renin antibody probes with cathepsin D has raised the possibility that this, or another aspartyl protease(s), may be present in these tissues (Hanssens et al., 1995a,b) . Since the putative DAP protease has extensive sequence similarity to both renin and cathepsin D (72 and 76%, respectively) it is possible that all three enzymes could be candidates for the molecules previously detected in gestational tissues with renin probes. This remains to be elucidated.
The DAP-1 and DAP-2 sequences isolated in this study are either coded for by separate genes or are derived from the same gene via alternative splicing. While our Southern data ( Figure 7) show that there are two homologous DAP gene loci in the human genome, there are features in common with other alternatively spliced genes that lead us to speculate on the involvement of this latter mechanism in the tissue-specific expression of active and inactive forms of the DAP protease. In particular, the premature termination of translation predicted by the DAP-2 sequence (caused by the 80 bp sequence additional to that seen in DAP-1) has striking similarity with the reported mechanism for regulation of the caspase-2 gene (ICH-2). For ICH-2, the alternative inclusion or exclusion of a 61 bp exon is involved in the production of two transcripts, ICH-1S and ICH-1L respectively. Inclusion of the 61 bp exon results in translation termination using a more upstream stop codon in Ich-1S generating a shorter inactive protein product (Jiang and Wu, 1999) .
Although some alternative splicing events appear to be constitutive, with mRNA variants coexisting at constant ratios in the same cells, this mechanism is also widely involved in the regulation of tissue and developmental stage-specific gene expression (Lopez, 1998; Jiang and Wu, 1999) . Not surprisingly, some human genetic diseases and developmental defects have been correlated with disruptions of alternative splicing control in particular genes (Lopez, 1998) . It is possible that tissue and developmental stage-specific expression of the DAP protease are important for the normal development and function of the uteroplacental tissues and that dysregulation of the control of DAP gene splicing may play a role in abnormal placentation, like that seen in pre-eclampsia.
